- Biden says 'working' to get people back to homes on Israel-Lebanon border
- Pope criticises Argentina's crackdown on protesters
- Court limits screenings of videos in France mass rape case
- Gurbaz century takes Afghanistan to 311-4 in 2nd ODI
- Central banks face 'difficult balancing act': IMF chief
- McLaren's Norris sets Singapore pace as struggling Verstappen 15th
- Guardiola tells players to lead change over workload fears
- Paris Olympics sports equipment moves to new homes
- 'Happy' Kinghorn relishing life at Toulouse
- Norris sets Singapore pace as Verstappen only 15th
- 8 dead in Israeli strike, source says Hezbollah commander killed
- Germany to bid to host women's Euro 2029
- Portugal brings deadly forest fires under control
- Postecoglou defends Solanke after slow start to Spurs career
- US nuclear plant Three Mile Island to reopen to power Microsoft
- Arteta urges Arsenal to take next step in Man City showdown
- Stock markets fall after Fed-fuelled rally
- Top Hezbollah commander 'killed' in Israel strike
- Poland charges Russian over attack on Navalny ally: prosecutors
- Man City have rest 'advantage' in Arsenal showdown: Guardiola
- Maresca has 'no doubt' in Jackson as Chelsea's number nine
- EU chief announces 35 bn euro loan plan for Ukraine before winter
- From TikTok to Hollywood, the irresistible rise of Italy's Khaby Lame
- Verstappen punished for swearing in Singapore press conference
- Sri Lanka lead by 202 in first New Zealand Test
- Brook 'not too fussed' by England's batting in heavy Australia loss
- India's Ashwin 'happy' to embrace pressure
- A modern 'Trojan Horse': two days of mayhem in Lebanon
- Third of Burundi mpox cases in children under five: UN
- Man Utd appoint Foster + Partners to develop Old Trafford 'masterplan'
- Israel-Hezbollah exchanges intensify on Lebanon border
- French mayor sorry for 'no one died' remark over mass rape trial
- Mohamed Al-Fayed, outsider shunned by British high society
- Lawyers say 'monster' late Harrods owner abused dozens of women
- India in box seat after Bumrah takes four against Bangladesh
- Taiwan retains death penalty but limits use to 'exceptional' cases
- Ferrari's Leclerc sets early pace in Singapore ahead of Norris
- 10 years into Huthi rule, some Yemenis count the cost
- France poised to finally get new govt
- Kompany, Alonso call for action on player workload amid strike talks
- Liverpool goalkeeper Alisson doubtful for Bournemouth clash
- Bumrah takes four as India bowl out Bangladesh for 149
- Sri Lanka 134-1 to take upper hand in first New Zealand Test
- Bayern's Kompany calls for game cap for players amid strike talks
- Christie's expands Hong Kong footprint in hope of art market 'pickup'
- Sultry screen legend Sophia Loren turns 90
- Cambodian opposition figure in court on incitement charge
- Bumrah takes three wickets to have Bangladesh in trouble at 112-8
- Kimchi threat as heatwave drives up South Korea cabbage prices
- UK economic data delivers fresh blow to new govt
CMSC | -0.04% | 25.11 | $ | |
NGG | 1.07% | 69.576 | $ | |
BCC | -1.03% | 143.21 | $ | |
SCS | -2.35% | 13.005 | $ | |
BP | -0.26% | 32.675 | $ | |
BCE | -0.69% | 34.95 | $ | |
BTI | -0.33% | 37.445 | $ | |
GSK | -1.57% | 40.978 | $ | |
RBGPF | 5.79% | 60.5 | $ | |
RYCEF | 0.14% | 6.96 | $ | |
RIO | -2.04% | 63.88 | $ | |
AZN | -0.67% | 78.375 | $ | |
JRI | -0.63% | 13.316 | $ | |
CMSD | 0.03% | 25.018 | $ | |
VOD | -0.35% | 10.025 | $ | |
RELX | -0.05% | 48.105 | $ |
Experts encouraged by Alzheimer drug preliminary data
Experts on Wednesday said they were encouraged after preliminary data for a new Alzheimer's drug showed it slowed cognitive decline, the first medicine to accomplish this goal.
The treatment, called lecanemab, was tested in a clinical trial of nearly 1,800 people, and slowed cognitive decline by 27 percent across an 18-month period, according to early results announced by makers Biogen and Eisai.
"This is the first drug that's been shown to not only remove the build-up of a protein called amyloid in the brain, but to have a small but statistically significant impact on cognitive decline in people with early-stage disease," said Susan Kohlhaas of Alzheimer's UK.
But experts cautioned their comments were tempered by the preliminary nature of the results, which were announced by press release ahead of publication in a peer-reviewed journal, as the companies look to bring the treatment to market as early as January 2023 in the United States.
Biogen previously brought another Alzheimer's drug to market called Aduhelm, but there was significant controversy over the evidence it worked, and its approval led to three high-level resignations in the US Food and Drug Administration.
According to a statement by Biogen and Eisai, in addition to slowing cognitive decline, the new treatment also slowed build-up in the brain of the protein amyloid, which forms sticky plaques and kills brain cells.
Side effects included higher rates of swelling and bleeding in the brain in the group that received the treatment compared to the group that received a placebo.
Both treatment and placebo groups had people of similar characteristics, including a broad range of underlying conditions. A quarter were either Hispanic or African American.
Michel Vounatsos, CEO of Biogen, said the announcement "gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer's disease."
Masud Husain, a professor of neurology at the University of Oxford, said in a statement: "While the summary of the results certainly seems very encouraging, we have to be cautious until we are allowed to review the data fully.
"It is also important to bear in mind that the trial results apply only to people with mild Alzheimer's disease, not everyone with the condition, and that there were important side effects of the drug, including bleeds in the brain."
P.Stevenson--AMWN